Warwick researchers develop new vehicle for drug release
Plankton inspires creation of ‘stealth’ armour for slow release microscopic drug vehicles
The scientists have been able to decorate these hollow structures with a variety of nanoparticles, opening a new strategy in the design of vehicles for drug release, for example by giving the vesicle ‘stealth’ capabilities which can avoid the body’s defences while releasing the drug.
Advances in polymerisation have boosted the creation of vesicles made from polymer molecules. Such vesicles have special chemical and physical properties, which make them potential drug delivery vehicles.
The University of Warwick team believed that more strength and tailored properties could be given to the vesicles if they could add an additional layer of colloidal ‘armour’ made from a variety of nanoparticles.
Lead researcher, Associate Professor Stefan Bon, said: ‘We took our inspiration from nature, in how it adds protection and mechanical strength in certain classes of cells and organisms. In addition to the mechanical strength provided by the cytoskeleton of the cell, plants, fungi, certain bacteria have an additional cell wall as outermost boundary.
‘Organisms that particularly attracted our interest were those with a cell wall composed of an armour of colloidal objects – for instance bacteria coated with S-layer proteins, or phytoplankton, such as the coccolithophorids, which have their own CaCO3-based nano-patterned colloidal armour.’
The Warwick researchers hit on a simple and effective method of adding different types of extra armour to the polymer-based vesicles. One example was a packed layer of microscopic polystyrene balls. Because the polystyrene balls had a crystalline-like ordered structure, the researchers could design a vesicle with an additional and precise permeable reinforced barrier for drug release.
The researchers used the same technique to add a gelatine-like polymer to provide ‘stealth’ armour to shield vesicles from unwanted attention from the body’s immune system while it slowly released its drug treatment.
This particular coating (a poly((ethyl acrylate)-co-(methacrylic acid)) hydrogel) absorbs so much surrounding water into its outer structure that it may be able to fool the body’s defence mechanism into believing it is in fact just water.
You may also like
Research & Development
Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform
Read moreIrish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Trending Articles
You may also like
Research & Development
Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing
Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform
The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering
Research & Development
Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption
A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Regulatory
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions
Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Pharmaceutical
Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026
Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16